OncoMatch/Clinical Trials/NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Is NCT06206174 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TGRX-814 for hematologic malignancy.
Treatment: TGRX-814 — The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: BCL-2 inhibitor
Exception: unless discontinued due to intolerance
received BCL-2 inhibitor therapy prior to the first dose of study drug, unless discontinued due to intolerance
Cannot have received: allogeneic hematopoietic stem cell transplantation
received allogeneic hematopoietic stem cell transplantation
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months
received autologous hematopoietic stem cell transplantation within 3 months
Cannot have received: monoclonal antibody antitumor therapy
Exception: within 4 weeks prior to the first dose
monoclonal antibody antitumor therapy within 4 weeks prior to the first dose
Cannot have received: CAR-T cell therapy
Exception: within 12 weeks prior to the first dose
participation in CAR-T therapy within 12 weeks prior to the first dose
Cannot have received: anticancer therapy/investigational therapy
Exception: within 14 days prior to the first dose, or has not recovered from clinically significant toxicity below grade 2 on prior therapy
received anticancer therapy/investigational therapy within 14 days prior to the first dose, or has not recovered from clinically significant toxicity below grade 2 on prior therapy
Cannot have received: steroidal anticancer therapy
Exception: within 7 days prior to the first dose of study drug
received steroidal anticancer therapy...within 7 days prior to the first dose of study drug
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
left ventricular ejection fraction ≤ 50% as assessed by cardiac ultrasound; prolonged QT interval; Grade III atrioventricular block or other arrhythmia requiring medical intervention; NYHA Class III or IV congestive heart failure; myocardial infarction or bypass surgery within 6 months prior to dosing; arterial or venous thrombotic events within 6 months prior to the first dose of study drug; other cardiovascular diseases that investigator deemed unfit for enrollment
adequate bone marrow function; adequate coagulation, hepatic and renal function; left ventricular ejection fraction ≤ 50% as assessed by cardiac ultrasound; prolonged QT interval; Grade III atrioventricular block or other arrhythmia requiring medical intervention; NYHA Class III or IV congestive heart failure; had myocardial infarction or experienced bypass surgery within 6 months prior to dosing; had arterial or venous thrombotic events within 6 months prior to the first dose of study drug; have other cardiovascular diseases that investigator deemed unfit for enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify